Erschienen in:
01.12.2010 | Editorial
Advances and challenges in phenylketonuria
verfasst von:
Cary O. Harding, Nenad Blau
Erschienen in:
Journal of Inherited Metabolic Disease
|
Ausgabe 6/2010
Einloggen, um Zugang zu erhalten
Excerpt
Phenylketonuria (PKU; OMIM 262600), one of the most common inborn errors of metabolism, is caused by recessively inherited deficiency of the enzyme phenylalanine hydroxylase (PAH; EC 1.14.16.1) (Blau et al.
2010). PAH catalyses the irreversible hydroxylation of phenylalanine (Phe) to tyrosine. PAH is expressed primarily in the liver but also in the kidney and pancreas, and its activity requires the unconjugated pterin co-factor, tetrahydrobiopterin (BH
4). PAH deficiency causes hyperphenylalaninaemia, but hyperphenylalaninaemia can also be caused by inherited deficiency of enzymes involved in BH
4 synthesis or recycling (Blau et al.
2010). Chronic, untreated, severe hyperphenylalaninaemia in infants and children leads to seizures and mental retardation. Newborn screening and early initiation of PKU therapy has eliminated the major manifestations of the disease, but shortcomings in our current therapeutic approach remain. …